Live Chat

CFD's zijn complexe instrumenten en gaan gepaard met een hoog risico snel kapitaal te verliezen als gevolg van hefboommechanismen. 74.2% an de retailbeleggers lijdt verlies op de handel in CFD's met deze aanbieder. U dient zorgvuldig te overwegen of u begrijpt hoe CFD's werken en of u het zich kunt veroorloven om hoge risico's te nemen op het verliezen van uw kapitaal.

Close

Handelen Vir Biotechnology VIR

VirBiotechnology live grafieken

instrument_fundamentals

Weekly Search
Weekly
Daily
Datum Sluit Verandering % verandering Openen Piek Bodem

Laatste marktnieuws

Bitcoin and Trump crypto market trends and impact.
Vanessa L 2025 Jan 24, 11:20

Trump Crypto Analysis and Insights

Cryptocurrencies
Close-up of gold bars on nugget grains, symbolizing metal prices today and commodity gold.
Vanessa L 2025 Jan 24, 10:40

Commodity Gold and Metal Prices Today

Forex Gold Commodities
USD to JPY forecast with currency chart showing forex market trends.
Vanessa L 2025 Jan 24, 10:30

BoJ Interest Rate Hike ; USD to JPY Forecast

Forex JPY USD
A graph showing us stock futures mildly decline after S&P 500 record close.
Vanessa L 2025 Jan 24, 06:30

US Stock Futures Decline After S&P 500 Record Close

Shares Stocks US500
Frances Wang 2025 Jan 23, 16:00

Tesla stock prediction 2025: forecast for the tesla share price

TSLA Stocks Shares
Frances Wang 2025 Jan 23, 16:00

Zuckerberg sold stock: He Sells $2 Billion in Meta Stock Amid AI Push

Stocks
Frances Wang 2025 Jan 23, 16:00

Financial compensation news: Car compensation may affect working people

CFD Trading
Tommy Yap 2025 Jan 23, 16:00

Morning Note: S&P 500 Reaches Record High Amid Trump’s Rate and Oil Policy Hints

Morning Note S&P 500 Oil

Info

Spread

0.14

Spread (%)

1.2704 %

Hefboom

1:5

Dagrente kopen

-0.0597 %

Dagrente verkopen

-0.0292 %

Valuta

USD

Openingstijden

Markt openen

Vrijdag

14:31 - 20:59

Maandag

14:31-20:59

Dinsdag

14:31-20:59

Woensdag

14:31-20:59

Donderdag

14:31-20:59

instr__analysis_statistics

Openen

---

Vorige Sluiten

---

52-weekse hoog/laag

--- – ---

Beurswaarde

1450191616

Uitstaande aandelen

137720000

Datum winstcijfer (volgende)

0000-00-00

Div. rend.

Ex-dividenddatum

Jaarlijks verwachte dividendpercentage

0

Jaarlijks verwachte dividendrendement

0

Winst per aandeel

-3.93

Meer informatie over dit instrument

Vir Biotechnology Vir Biotechnology Inc
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company's preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.

Gerelateerde instrumenten

Activa
Verkoop
Koop
% verandering
Gerelateerde instrumenten
Trustpilot
Live Chat